Cargando…

A146 THE EFFECTIVENESS OF USTEKINUMAB DOSE ESCALATION IN PATIENTS WITH ULCERATIVE COLITIS

BACKGROUND: Ustekinumab (UST), an IgG1 antibody that targets IL-12/23, is an effective and safe treatment option for patients with inflammatory bowel disease (IBD). Cohort studies have shown that dose escalation is an effective strategy for reinducing and maintaining remission in Crohn’s disease pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Albino, L, Rosentreter, R, Lu, C, Siffledeen, J, Dieleman, L A, Ma, C, Baugmart, D C, Du, L, Halloran, B, Kroeker, K, Peerani, F, Wong, K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Poster of Distinction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859317/ http://dx.doi.org/10.1093/jcag/gwab049.145

Ejemplares similares

A57 ULCERATIVE COLITIS DISEASE ACTIVITY IS DOMINATED BY INNATE IMMUNITY AND FEATURES OF TISSUE REMODELING
por: Madill-Thomsen, K, et al.
Publicado: (2022)

A160 MOLECULAR ANALYSIS OF THE INJURY-REPAIR RESPONSE IN ULCERATIVE COLITIS REVEALS HETEROGENEITY IN DISEASE ACTIVIT
por: Madill-Thomsen, K, et al.
Publicado: (2022)

A171 EXPLORING PATIENT PERSPECTIVES ON A 12-WEEK, ONLINE STRESS REDUCTION INTERVENTION IN INFLAMMATORY BOWEL DISEASE
por: Hyde, A, et al.
Publicado: (2022)

A93 USEFULNESS OF A NOVEL SMARTPHONE APP IN GASTROINTESTINAL ENDOSCOPY TO TRACK PROCEDURE NUMBERS AND THERAPEUTIC INTERVENTIONS
por: Yang, D Y, et al.
Publicado: (2022)

A204 COST-EFFECTIVENESS OF THERAPIES AFTER FAILURE OF CONVENTIONAL THERAPY FOR PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS IN THE CANADIAN HEALTHCARE SYSTEM
por: Hagerman, C, et al.
Publicado: (2023)

A158 COMPARING CORTIMENT® AND PREDNISONE IN ULCERTATIVE COLITIS: A POPULATION-BASED STUDY OF OUTCOMES
por: Coward, S, et al.
Publicado: (2022)

A54 DIETARY COMPONENTS ARE ASSOCIATED WITH FECAL CALPROTECTIN IN ULCERATIVE COLITIS
por: Chiu, E, et al.
Publicado: (2022)

A150 ASSOCIATION BETWEEN SERUM USTEKINUMAB CONCENTRATIONS AND ENDOSCOPIC DISEASE ACTIVITY IN CROHN’S DISEASE
por: Yanofsky, R, et al.
Publicado: (2022)

A154 COMPARING RESPONSE TO INTRAVENOUS IRON INFUSION IN CROHN’S DISEASE AND ULCERATIVE COLITIS
por: Su, S, et al.
Publicado: (2022)

A38 INVESTIGATION OF POST-TRANSLATIONAL MODIFICATIONS IN SERUM OF CROHN’S DISEASE PATIENTS USING A PROTEOMICS APPROACH
por: De Almeida, L G N, et al.
Publicado: (2023)

A235 ILEAL MICROBIOME ALPHA DIVERSITY REMAINS LOWER IN ENDOSCOPICALLY AND HISTOLOGICALLY INACTIVE CROHN’S DISEASE COMPARED TO ULCERATIVE COLITIS OR HEALTHY CONTROLS
por: Olivera Sendra, P A, et al.
Publicado: (2022)

A87 HEALTHCARE PROVIDER SATISFACTION WITH VIRTUAL CARE DELIVERY IN ALBERTA DURING THE COVID-19 PANDEMIC.
por: Olayinka, L, et al.
Publicado: (2021)

A156 MUCOSA-ASSOCIATED MICROBIOTA OF ILEOCOLONIC CROHN’S DISEASE PATIENTS IS DISTINCT FROM COLONIC CROHN’S DISEASE AND ULCERATIVE COLITIS PATIENTS INDEPENDENT OF BIOPSY SITE, ENDOSCOPIC INFLAMMATION AND HOST GENETICS
por: Hernandez-Rocha, C, et al.
Publicado: (2022)

A182 THE LACK OF CHROMOGRANIN A IMPACTS COLONIC EPITHELIAL CELLS MARKERS IN AN EXPERIMENTAL MODEL OF ULCERATIVE COLITIS
por: Tshikudi, D M, et al.
Publicado: (2022)

A65 PREDICTING TRANSITION SUCCESS IN YOUNG ADULTS WITH INFLAMMATORY BOWEL DISEASE: PRELIMINARY RESULTS
por: Bihari, A, et al.
Publicado: (2022)

A36 NON-PSYCHOTROPIC PHYTOCANNABINOIDS ATTENUATE VISCERAL HYPERSENSITIVITY IN DEXTRAN SULFATE SODIUM (DSS)-INDUCED COLITIS
por: Svendsen, K, et al.
Publicado: (2022)

A145 EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY
por: Panaccione, R, et al.
Publicado: (2022)

A101 BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM OCCURRING POST-LIVER TRANSPLANT FOR PSC WITH CLINICAL REMISSION OF ULCERATIVE COLITIS AFTER STEM CELL TRANSPLANTATION
por: Donaldson, M A, et al.
Publicado: (2022)

A175 DISEASE ACTIVITY IN FIRST TRIMESTER IS ASSOCIATED WITH REDUCED GROWTH IN INFANTS BORN TO WOMEN WITH INFLAMMATORY BOWEL DISEASE
por: Wu, R Y, et al.
Publicado: (2022)

A51 INTESTINAL MICROBIOTA DETERMINES ARYL HYDROCARBON RECEPTOR ACTIVATION AND SUSCEPTIBILITY TO COLITIS
por: Rondeau, L, et al.
Publicado: (2023)

Persistence and Dose Escalation During Maintenance Phase and Use of Nonbiologic Medications Among Patients With Ulcerative Colitis Initiated on Ustekinumab in the United States
por: Zhdanava, Maryia, et al.
Publicado: (2023)

A35 DNA HYPOMETHYLATION INHIBITS TUFT CELL-DERIVED COLITIS-ASSOCIATED CANCER
por: Larsen, F, et al.
Publicado: (2022)

A48 OPTIMIZATION OF TRYPTOPHAN-CONTAINING DIETS TO ACTIVATE THE ARYL HYDROCARBON RECEPTOR AND REDUCE SUSCEPTIBILITY TO COLITIS
por: Rondeau, L, et al.
Publicado: (2022)

A48 LYOPHILIZED FECAL MICROBIOTA TRANSPLANT (FMT) DELAYS THE ONSET OF SPONTANEOUS COLITIS IN MUC2-/- MICE
por: Chan, J J, et al.
Publicado: (2023)

A27 DNA HYPOMETHYLATION INDUCED BY 5-AZA-CDR OR LOSS OF DNMT1 INHIBITS COLITIS-ASSOCIATED COLORECTAL CANCER
por: Larsen, F, et al.
Publicado: (2023)

A54 THE IMPACT OF NON-INVASIVE TRANSCUTANEOUS AURICULAR VAGUS NERVE STIMULATION (NITAVNS) ON THE DEVELOPMENT OF EXPERIMENTAL COLITIS IN MICE
por: Hesampour, F, et al.
Publicado: (2023)

A32 PHAGE TREATMENT DELAYS ONSET OF CROHN’S-ASSOCIATED E. COLI DRIVEN COLITIS IN MICE COLONIZED WITH A DEFINED MICROBIOTA
por: Jackson, K, et al.
Publicado: (2023)

A165 VEDOLIZUMAB IS AN OPTION TO TREAT MICROSCOPIC COLITIS IN PATIENTS DEPENDENT ON ORAL STEROIDS OR HAVE FAILED A BIOLOGIC: A MULTICENTRE CANADIAN CASE SERIES
por: Kulyk, A, et al.
Publicado: (2022)

A28 RESPONSE RATE OF VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD) PATIENTS TO ANTI-TNF TREATMENT IS HIGHER THAN PREVIOUSLY REPORTED, BUT HIGHER DOSING IS REQUIRED-A LARGE TERTIARY SINGLE CENTER EXPERIENCE
por: Eindor, A, et al.
Publicado: (2022)

A47 MICROBIAL FUNCTIONS AS BIOMARKERS OF PRO-INFLAMMATORY RESPONSE TO SELECT DIETARY FIBERS IN IBD
por: Armstrong, H, et al.
Publicado: (2022)

A44 PGC1-α INHIBITION WORSENS DSS-INDUCED COLITIS IN MICE
por: Oliveira Ponce, J P, et al.
Publicado: (2022)

Combining Cyclosporine With Ustekinumab in Acute Severe Ulcerative Colitis
por: Shaffer, Seth R., et al.
Publicado: (2021)

A31 OUTCOMES OF PATIENTS UNDERGOING REPEAT VIDEOCAPSULE ENDOSCOPY (VCE) PRESENTING WITH OBSCURE GASTROINTESTINAL BLEEDING (OGIB)
por: Krahn, T, et al.
Publicado: (2022)

A26 BMP-SIGNALING IMPAIRED TELOCYTES CREATE A DISRUPTED NICHE GRADIENT FOSTERING COLITIS-ASSOCIATED CANCER
por: Reyes, V, et al.
Publicado: (2023)

Ustekinumab dose escalation improves clinical responses in refractory Crohn’s disease
por: Haider, Syedreza A., et al.
Publicado: (2020)

A121 QUANTIFYING INTER-OBSERVER VARIABILITY IN THE SEGMENTATION OF RECTAL TUMORS IN ENDOSCOPY IMAGES AND ITS EFFECTS ON DEEP LEARNING
por: Weishaupt, L L, et al.
Publicado: (2022)

A49 TWO NOVEL LIVE BIOTHERAPEUTIC PRODUCTS PROTECT DSS-EXPOSED MICE FROM ACUTE COLITIS WHEN COMPARED TO 5-ASA
por: Verdugo Meza, A, et al.
Publicado: (2023)

Rapid Induction and Maintenance of Remission in Refractory Ulcerative Colitis with Ustekinumab
por: Chen, An-Yu, et al.
Publicado: (2019)

Ustekinumab in ulcerative colitis‐ insights from the real‐world data
por: Veisman, Ido, et al.
Publicado: (2022)

Diffuse Panbronchiolitis in a Patient With Ulcerative Colitis Treated With Ustekinumab
por: Marmor, Meghan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_focq4qa58o0itbvkkk4e4of5eg